As of 12:04pm ET
| -0.089 / -1.61%|
The 2 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 13.75, with a high estimate of 15.00 and a low estimate of 12.50. The median estimate represents a +152.71% increase from the last price of 5.44.
The current consensus among 4 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.